A Global Digital Media Network

DUBLIN–(Business Wire)–The “Acne Drugs: Global Markets” report has been added to ResearchAndMarkets.com’s offering.

This report offers a detailed picture of the acne drug market. It highlights the current and future market potential for acne drugs and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, and trends in the market. The report also covers market projections through 2025 as well as key market players.

This report details market shares for acne drugs based on drug type, route of administration, distribution channel, and geography. Based on drug type, the market is segmented into the retinoid, antibiotics, hormonal agent, and other segments. Based on the route of administration, the market is segmented into topical and oral. Based on the distribution channel, the market segmented into prescription-based and over the counter (OTC).

By geography, the market has been segmented into North and South America, Europe, Asia-Pacific, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India) are covered in regional segments. For market estimates, data have been provided for 2020 as the base year, with forecasts for 2020 through 2025. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The Report Includes:

Estimation of the market size and analyses of global market trends, with data from 2018 and 2019, estimated data for 2020, and projections of compound annual growth rates (CAGRs) through 2025

Highlights of current and future market potential, market size, and market share analysis based on drug type, mode of administration, distribution channel, and region

Analysis of market trends and explanation of factors driving and restraining the growth of the global acne drugs market

Discussion on the impact of coronavirus on the global economy and information on government expenditures on COVID-19

Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and new product launches in the market

Comprehensive company profiles of major players of the industry, including Allergan, Bausch Health, Galderma, GlaxoSmithKline PLC, and Pfizer Inc.

Key Topics Covered:

Chapter 1 Introduction

Introduction

Study Goals and Objectives

Reasons for Doing This Study

Scope of Report

Information Sources

Methodology

Geographic Breakdown

Analyst’s Credentials

Custom Research

Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Overview of Acne Drugs

Comedonal

Papulopustular

Nodulocystic

History of Outbreaks

Regulatory Scenario

Regulations in the U.S.

Chapter 4 Economic Impact of COVID-19

Impact of COVID-19 on the Global Economy

Government Expenditures on COVID-19

Impact of COVID-19 on Pharma Supply Chains

Disruption of Clinical Trials

Impact on Insurance Providers

Impact on Health Technology Assessment

The threat to Healthcare Acquisitions

Chapter 5 Market Dynamics

Market Drivers

Overview

Increasing Prevalence of Acne and Facial Skin Diseases

Unhealthy Eating Habits and Lifestyles Worldwide

Rise in Adoption of Skin Care Products

Growing Acne Cases in Geriatric Population

Market Restraints

Side Effects Associated with Medication

Presence of Alternatives for Acne Treatment

Market Opportunities

Unmet Needs in Low- and Middle-Income Countries

Macroeconomic Indicators

Chapter 6 Market Factor Analysis

Porter’s Five Forces Model

Bargaining Power of Suppliers

Bargaining Power of Buyers

The threat of New Entrants

Threat of Substitutes

Intensity of Rivalry

Value Chain Analysis

R&D

Clinical Testing

Manufacturing

Marketing and Sales

Post-Sales Services

Chapter 7 Market Breakdown by Drug Type

Global Market for Acne Drugs by Drug Type

Retinoid

Antibiotics

Hormonal Agents

Others

Chapter 8 Market Breakdown by Route of Administration

Global Market for Acne Drugs by Route of Administration

Topical

Oral

Chapter 9 Market Breakdown by Distribution Channel

Global Market for Acne Drugs by Distribution Channel

Over-the-Counter

Prescription Based

Chapter 10 Market Breakdown by Region

Global Market for Acne Drugs by Region

North and South America

United States

Canada

Europe

Germany

U.K.

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

India

Japan

Australia

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Size and Forecast

Chapter 11 Competitive Landscape

Global Company Ranking

Global Acne Drug Market Insights

Chapter 12 Company Profiles

Allergan

Bausch Health Companies Inc.

F. Hoffmann-La Roche Ltd.

Galderma

Glaxosmithkline Plc

Mylan N.V.

Pfizer Inc.

Perrigo

Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/qazu3s
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005441/en/

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
,
Digital Journal

A Global Digital Media Network

New York, Sept. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Polyurethane Additives Market Research Report by Type, by Application, by End-Use – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05975614/?utm_source=GNWThe Global Polyurethane Additives Market is expected to grow from USD 3,609.49 Million in 2019 to USD 4,875.38 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.13%.Market Segmentation & Coverage:This research report categorizes the Polyurethane Additives to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the Polyurethane Additives Market studied across Catalysts, Fillers, Flame Retardants, and Surfactants. Based on Application, the Polyurethane Additives Market studied across Adhesives & Sealants, Coatings, Elastomers, and Foams. Based on End-Use, the Polyurethane Additives Market studied across Automotive & Transportation, Bedding & Furniture, Building & Construction, and Electronics. Based on Geography, the Polyurethane Additives Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Polyurethane Additives Market including Albemarle Corporation, Basf SE, Covestro AG, Dow Inc., Drd Additive, Eastman Chemical Company, Everlight Chemical Industrial Corp, Evonik Industries, Evonik Industries AG, Galata Chemicals, Gulbrandsen Chemicals, Inc., Huntsman International LLC, Isothane Ltd, Kao Corporation, Lanxess AG, Momentive, Tosoh Corporation, Vanderbilt Chemicals, LLC, Wacker Chemie AG, Wanhua Chemical Group Co., Ltd., and Worlee. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Polyurethane Additives Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Polyurethane Additives Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Polyurethane Additives Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Polyurethane Additives Market?4. What is the competitive strategic window for opportunities in the Global Polyurethane Additives Market?5. What are the technology trends and regulatory frameworks in the Global Polyurethane Additives Market?6. What are the modes and strategic moves considered suitable for entering the Global Polyurethane Additives Market?Read the full report: https://www.reportlinker.com/p05975614/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________,
Digital Journal

A Global Digital Media Network

Read the full report: https://www.reportlinker.com/p05957565/?utm_source=GNWI. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Oncology Molecular Diagnostics Competitor Market Share Scenario Worldwide (in %): 2018E 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 2: World Historic Review for Oncology Molecular Diagnostics by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 3: World 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027 Table 4: World Current & Future Analysis for Breast Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 5: World Historic Review for Breast Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 6: World 15-Year Perspective for Breast Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 7: World Current & Future Analysis for Colorectal Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 8: World Historic Review for Colorectal Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 9: World 15-Year Perspective for Colorectal Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 10: World Current & Future Analysis for Prostate Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 11: World Historic Review for Prostate Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 12: World 15-Year Perspective for Prostate Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 13: World Current & Future Analysis for Cervical Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 14: World Historic Review for Cervical Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 15: World 15-Year Perspective for Cervical Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 16: World Current & Future Analysis for Other Disease Types by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 17: World Historic Review for Other Disease Types by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 18: World 15-Year Perspective for Other Disease Types by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 19: World Current & Future Analysis for Instruments by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 20: World Historic Review for Instruments by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 21: World 15-Year Perspective for Instruments by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 22: World Current & Future Analysis for Reagents by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 23: World Historic Review for Reagents by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 24: World 15-Year Perspective for Reagents by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 Table 25: World Current & Future Analysis for Other Segments by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 26: World Historic Review for Other Segments by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 27: World 15-Year Perspective for Other Segments by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Oncology Molecular Diagnostics Market Share (in %) by Company: 2018 & 2027 Market Analytics Table 28: USA Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 29: USA Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 30: USA 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 31: USA Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 32: USA Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 33: USA 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 CANADA Table 34: Canada Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 35: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 36: Canada 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 37: Canada Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 38: Canada Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 39: Canada 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 JAPAN Table 40: Japan Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 41: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 42: Japan 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 43: Japan Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 44: Japan Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 45: Japan 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 CHINA Table 46: China Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 47: China Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 48: China 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 49: China Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 50: China Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 51: China 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 EUROPE Market Facts & Figures European Oncology Molecular Diagnostics Market: Competitor Market Share Scenario (in %) for 2018 & 2027 Market Analytics Table 52: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 53: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 54: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2018 & 2027 Table 55: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 56: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 57: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 58: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 59: Europe Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 60: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 FRANCE Table 61: France Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 62: France Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 63: France 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 64: France Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 65: France Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 66: France 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 GERMANY Table 67: Germany Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 68: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 69: Germany 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 70: Germany Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 71: Germany Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 72: Germany 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 ITALY Table 73: Italy Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 74: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 75: Italy 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 76: Italy Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 77: Italy Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 78: Italy 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 UNITED KINGDOM Table 79: UK Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 80: UK Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 81: UK 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 82: UK Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 83: UK Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 84: UK 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 SPAIN Table 85: Spain Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 86: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 87: Spain 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 88: Spain Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 89: Spain Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 90: Spain 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 RUSSIA Table 91: Russia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 92: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 93: Russia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 94: Russia Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 95: Russia Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 96: Russia 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 REST OF EUROPE Table 97: Rest of Europe Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 98: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 99: Rest of Europe 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 100: Rest of Europe Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 101: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 102: Rest of Europe 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 ASIA-PACIFIC Table 103: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 104: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 105: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027 Table 106: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 107: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 108: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 109: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 110: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 111: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 AUSTRALIA Table 112: Australia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 113: Australia Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 114: Australia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 115: Australia Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 116: Australia Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 117: Australia 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 INDIA Table 118: India Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 119: India Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 120: India 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 121: India Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 122: India Historic Review for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 123: India 15-Year Perspective for Oncology Molecular Diagnostics by Segment – Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027 SOUTH KOREA Table 124: South Korea Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 125: South Korea Historic Review for Oncology Molecular Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets – Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 126: South Korea 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type – Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027 Table 127: South Korea Current & Future Analysis for Oncology Molecular Diagnostics by Segment – Instruments, Reagents and Other Segments – Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 128: South Korea Historic Review for Oncology Molecular Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p05957565/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________,
Digital Journal

A Global Digital Media Network

DUBLIN–(Business Wire)–The “Global Remote Patient Monitoring Device Market Outlook 2027” report has been added to ResearchAndMarkets.com’s offering.

The worldwide market of remote patient monitoring is anticipated to achieve a CAGR of 14.94% during the forecast period, i.e. 2020-2027.

Factors such as rising incidences of cardiovascular disorders amongst individuals, coupled with factors such as favorable government policies, advancement in healthcare facilities and the changes observed in the adoption of remote patient monitoring services are some of the factors anticipated to promote the growth of the global remote patient monitoring market. The market is also thriving owing to the opportunities that are derived from increasing R&D investments for the development of healthcare infrastructure and the strategic collaborations and partnerships amongst manufacturers in the healthcare industry.

Moreover, growing concern for the increasing number of chronic diseases worldwide coupled with increasing number of diabetic patients, increasing funding by the governments of nations for R&D and the advancements in the quality of healthcare services are some of the factors anticipated to drive the growth of the global remote patient monitoring market.

The global remote patient monitoring market consists of various segments that are segmented by product, type, end user and by region. The type segment is further sub-divided into wireless and wired, out of which, the wireless segment is anticipated to hold the largest market share and grow with a CAGR of 15.31% during the forecast period. Additionally, the segment is also anticipated to attain an absolute $ opportunity of USD 5,931.85 million during the forecast period. On the other hand, the hospital segment, which is a sub-segment of the end-user segment, is anticipated to hold the largest market share and attain a value of USD 883.62 million by the end of 2027 by growing at a CAGR of 14.63% during the forecast period.

Based on region, the global remote patient monitoring market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Asia Pacific, which had accounted for 20.97% share in the year 2018, is estimated to grow with a CAGR of 16.06% over the forecast period owing to the rising geriatric population and increasing demand for advanced monitoring solutions.

Some of the affluent industry leaders in the global remote patient monitoring market are BioTelemetry, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Resideo Technologies, Inc., Abbott, Boston Scientific Corporation, General Electric Company (GE Healthcare), Medtronic, F. Hoffmann-La Roche Ltd and ZOLL Medical Corporation.

Key Topics Covered

  1. Introduction

  2. Assumptions and Acronyms

  3. Research Methodology

  4. Executive Summary

  5. Key Market Opportunities

  6. Regulatory Landscape

  7. Analysis of Market Dynamics

7.1. Growth Drivers

7.2. Restraints

7.3. Key Trends

  1. Epidemiology Analysis

8.1. Diabetes

8.2. Cardiovascular Disorders

8.3. Respiratory Disorders

8.4. Cancer

  1. Risk Analysis

9.1. Demand Risk Analysis

9.2. Supply Risk Analysis

  1. Global Remote Patient Monitoring Market Outlook

10.1. Market Size and Forecast, 2018-2027

10.1.1. By Value (USD Million)

10.2. Global Remote Patient Monitoring Market Segmentation, 2018-2027

10.2.1. By Product

10.2.2. By Type

10.2.3. By End-user

10.2.4. By Region

  1. Competitive Structure

11.1. Detailed Overview

11.2. Assessment of Key Product Offerings

11.3. Analysis of Growth Strategies

11.4. Key Collaborations and Joint Ventures

11.5. Key Mergers and Acquisitions

11.6. Recent News and Developments

11.7. Key Clients and Partners

11.8. Exhaustive Analysis on Key Financial Indicators

11.9. Company Profiles of Global Remote Patient Monitoring Market

11.9.1. Biotelemetry Inc.

11.9.2. Mindray

11.9.3. Resideo

11.9.4. Abbott

11.9.5. Boston Scientific

11.9.6. GE Healthcare

11.9.7. Medtronic

11.9.8. Roche

11.9.9. Zoll Medical

  1. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/lvl5en
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005473/en/

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
,
Digital Journal

Leave a Reply

%d bloggers like this: